Advice
Following a full submission
Etonogestrel / ethinylestradiol vaginal ring (NuvaRing) is not recommended for use within NHS Scotland for contraception. Results from two randomised phase III clinical studies indicate that the contraceptive efficacy of NuvaRing is similar to that of two combined oral contraceptives.
NuvaRing produces good cycle control and is associated with high user acceptability.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice99KB (PDF)
Medicine details
- Medicine name:
- etonogestrel/ethinyl estradiol vaginal ring (NuvaRing)
- SMC ID:
- 502/08
- Indication:
- Contraception
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 February 2009